ScholarIQanswers from OpenAlex & ORCID
Malcolm D. Mason
ResearcherPublications, citations & collaboration network
Malcolm D. Mason is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Malcolm D. Mason have?
ScholarIQindexed works
Malcolm D. Mason has 443 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Malcolm D. Mason have?
ScholarIQcitation count
Malcolm D. Mason has 48,138 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Malcolm D. Mason?
ScholarIQh-index
Malcolm D. Mason has an h-index of 94 in OpenAlex.
What is the i10-index of Malcolm D. Mason?
ScholarIQi10-index
Malcolm D. Mason has an i10-index of 246 in OpenAlex.
What is the ORCID of Malcolm D. Mason?
ScholarIQorcid
The ORCID for Malcolm D. Mason is on the source record.
What is the OpenAlex record for Malcolm D. Mason?
ScholarIQopenalex
The OpenAlex for Malcolm D. Mason is on the source record.
What are the most-cited papers on Malcolm D. Mason?
ScholarIQmost cited works
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Freddie C. Hamdy, Jenny Donovan, J. Athene Lane, Malcolm D. Mason, Chris Metcalfe, Peter Holding, Michael Davis, T. J. Peters, Emma L. Turner, Richard M. Martin, Jon Oxley, Mary Robinson, John Staffurth, Eleanor Walsh, Prasad Bollina, James W.F. Catto, Andrew Doble, Alan Doherty, David Gillatt, Roger Kockelbergh, Howard Kynaston, Alan Paul, Philip Powell, Stephen M. Prescott, Derek J. Rosario, Edward Rowe, David E. Neal
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James, Matthew R. Sydes, Noel W. Clarke, Malcolm D. Mason, David P. Dearnaley, Melissa Spears, A.W.S. Ritchie, Christopher Parker, John M. Russell, Gerhardt Attard, Johann S. de Bono, William Cross, Robert J. Jones, George N. Thalmann, Claire Amos, David Matheson, Robin Millman, Mymoona Alzouebi, S. Beesley, Alison Birtle, Susannah Brock, Richard Cathomas, Prabir Chakraborti, Simon Chowdhury, Audrey Cook, Tony Elliott, Joanna Gale, Stephanie Gibbs, John D. Graham, John Hetherington, Robert Hughes, Robert Laing, Fiona McKinna, Duncan B. McLaren, Joe M. O’Sullivan, Omi Parikh, C. Peedell, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Rajaguru Srinivasan, John Staffurth, Santhanam Sundar, Shaun Tolan, David Tsang, John Wagstaff, Mahesh Parmar
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James, Johann S. de Bono, Melissa Spears, Noel W. Clarke, Malcolm D. Mason, David P. Dearnaley, A.W.S. Ritchie, Claire Amos, Clare Gilson, Robert J. Jones, David Matheson, Robin Millman, Gerhardt Attard, Simon Chowdhury, William Cross, Silke Gillessen, Christopher Parker, John M. Russell, Dominik Berthold, Chris Brawley, F. Adab, San Aung, Alison Birtle, Jo Bowen, Susannah Brock, Prabir Chakraborti, Catherine Ferguson, Joanna Gale, Emma Gray, Mohan Hingorani, Peter Hoskin, J.F. Lester, Zafar Malik, Fiona McKinna, Neil McPhail, Julian Money‐Kyrle, Joe M. O’Sullivan, Omi Parikh, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Carys Thomas, John Wagstaff, James Wylie, Anjali Zarkar, Mahesh Parmar, Matthew R. Sydes
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Jenny Donovan, Freddie C. Hamdy, J. Athene Lane, Malcolm D. Mason, Chris Metcalfe, Eleanor Walsh, Jane Blazeby, T. J. Peters, Peter Holding, Susan Bonnington, Teresa Lennon, Lynne Bradshaw, Deborah Cooper, Phillipa Herbert, Joanne Howson, Amanda Jones, Norma Lyons, E. George Salter, Pauline Thompson, Sarah Tidball, Jan Blaikie, Catherine Gray, Prasad Bollina, James W.F. Catto, Andrew Doble, Alan Doherty, David Gillatt, Roger Kockelbergh, Howard Kynaston, Alan Paul, Philip A. Powell, Stephen M. Prescott, Derek J. Rosario, Edward Rowe, Michael J. Davis, Emma L. Turner, Richard M. Martin, David E. Neal
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher Parker, Nicholas D. James, Chris Brawley, Noel W. Clarke, Alex Hoyle, Adnan Ali, A.W.S. Ritchie, Gerhardt Attard, Simon Chowdhury, William Cross, David P. Dearnaley, Silke Gillessen, Clare Gilson, Robert J. Jones, Ruth E. Langley, Zafar Malik, Malcolm D. Mason, David Matheson, Robin Millman, John M. Russell, George N. Thalmann, Claire Amos, Roberto Alonzi, Amit Bahl, Alison Birtle, Omar Din, Hassan Douis, Chinnamani Eswar, Joanna Gale, Melissa Gannon, Sai Jonnada, Sara Khaksar, J.F. Lester, Joe M. O’Sullivan, Omi Parikh, Ian Pedley, Delia Pudney, D.J. Sheehan, Narayanan Srihari, Anna Tran, Mahesh Parmar, Matthew R. Sydes